Literature DB >> 18222354

A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study.

Dov Shiffman1, Daniel I Chasman, Robert Y L Zee, Olga A Iakoubova, Judy Z Louie, James J Devlin, Paul M Ridker.   

Abstract

OBJECTIVES: We asked if carriers of the 719Arg allele of kinesin family member 6 (KIF6) have increased risk of coronary heart disease (CHD) in a cohort of initially healthy Caucasian American women.
BACKGROUND: The 719Arg allele of KIF6 (rs20455) has been reported to be associated with increased risk of CHD in a large population-based prospective study, ARIC (Atherosclerosis Risk in Communities), and in the placebo arms of 2 statin trials, CARE (Cholesterol and Recurrent Events) and WOSCOPS (West of Scotland Coronary Prevention Study). However, this KIF6 variant was not specifically investigated in the female subgroup in the ARIC study, and the CARE and WOSCOPS trials included only a small number of female patients.
METHODS: Genotypes of the rs20455 single nucleotide polymorphism (SNP) were determined among 25,283 initially healthy Caucasian women, age 45 years and older, participating in the WHS (Women's Health Study) who were prospectively followed over a 12-year period for incident cardiovascular events. The risk associated with the 719Arg allele of KIF6 was estimated using Cox proportional hazards models that adjusted for age and traditional risk factors.
RESULTS: During follow-up, 953 women suffered a first-ever CHD event (myocardial infarction, coronary revascularization, or cardiovascular death) or first-ever ischemic stroke. Compared with noncarriers, carriers of the 719Arg allele had an increased risk of CHD (hazard ratio [HR] = 1.24 [95% confidence interval (CI) 1.04 to 1.46, p = 0.013]) and myocardial infarction (HR = 1.34 [95% CI 1.02 to 1.75, p = 0.034]) but not ischemic stroke.
CONCLUSIONS: Confirming and extending previous reports, carriers of the 719Arg allele of KIF6 have 34% higher risk of myocardial infarction and 24% higher risk of CHD compared with noncarriers among 25,283 women from the WHS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18222354     DOI: 10.1016/j.jacc.2007.09.044

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  41 in total

Review 1.  Emerging clinical applications in cardiovascular pharmacogenomics.

Authors:  Samir B Damani; Eric J Topol
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010-08-20

2.  Family coronary heart disease: a call to action.

Authors:  H Robert Superko; Robert Roberts; Brenda Garrett; Lakshmana Pendyala; Spencer King
Journal:  Clin Cardiol       Date:  2010-12       Impact factor: 2.882

3.  Surprises of the genome and "personalized" medicine.

Authors:  Ali J Marian
Journal:  J Am Coll Cardiol       Date:  2008-01-29       Impact factor: 24.094

Review 4.  The microeconomics of personalized medicine: today's challenge and tomorrow's promise.

Authors:  Jerel C Davis; Laura Furstenthal; Amar A Desai; Troy Norris; Saumya Sutaria; Edd Fleming; Philip Ma
Journal:  Nat Rev Drug Discov       Date:  2009-03-20       Impact factor: 84.694

Review 5.  Genomic view of factors leading to plaque instability.

Authors:  Sonny Dandona; Robert Roberts
Journal:  Curr Cardiol Rep       Date:  2009-07       Impact factor: 2.931

Review 6.  Interdisciplinary Models for Research and Clinical Endeavors in Genomic Medicine: A Scientific Statement From the American Heart Association.

Authors:  Kiran Musunuru; Pankaj Arora; John P Cooke; Jane F Ferguson; Ray E Hershberger; Kathleen T Hickey; Jin-Moo Lee; João A C Lima; Joseph Loscalzo; Naveen L Pereira; Mark W Russell; Svati H Shah; Farah Sheikh; Thomas J Wang; Calum A MacRae
Journal:  Circ Genom Precis Med       Date:  2018-06

7.  Organ system heterogeneity DB: a database for the visualization of phenotypes at the organ system level.

Authors:  Deepthi Mannil; Ingo Vogt; Jeanette Prinz; Monica Campillos
Journal:  Nucleic Acids Res       Date:  2014-10-13       Impact factor: 16.971

Review 8.  How do we improve patient compliance and adherence to long-term statin therapy?

Authors:  Patricia Maningat; Bruce R Gordon; Jan L Breslow
Journal:  Curr Atheroscler Rep       Date:  2013-01       Impact factor: 5.113

9.  KIF6 p.Trp719Arg Testing to Assess Risk of Coronary Artery Disease and/or Statin Response.

Authors:  Diane Allingham-Hawkins; Andrew Lea; Susan Levine
Journal:  PLoS Curr       Date:  2010-10-21

10.  Investigation of KIF6 Trp719Arg in a case-control study of myocardial infarction: a Costa Rican population.

Authors:  Lance A Bare; Edward A Ruiz-Narvaéz; Carmen H Tong; Andre R Arellano; Charles M Rowland; Joseph J Catanese; Frank M Sacks; James J Devlin; Hannia Campos
Journal:  PLoS One       Date:  2010-09-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.